Human Insulin Drugs and Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The human insulin drug and delivery device market is set to witness a CAGR of more than 3% during the forecast period. The human insulin drug and delivery device market is segmented into type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins), device type (insulin pens, insulin pumps, insulin syringes, and jet injectors), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD million) and volume (in units million) for the above segments.

Home right-chevron-icon Market Analysis right-chevron-icon Healthcare Research right-chevron-icon Device Drug Combination Research right-chevron-icon Drug Filled Devices Research right-chevron-icon Human Insulin Drugs and Delivery Devices Market

Human Insulin Drugs and Delivery Devices Market Size

Human Insulin Drugs and Delivery Devices Market Summary
share button
Study Period 2017- 2028
Market Size (2023) USD 65.02 Billion
Market Size (2028) USD 78.08 Billion
CAGR (2023 - 2028) 3.73 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Human Insulin Drugs and Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Human Insulin Drugs and Delivery Devices Market Analysis

The Human Insulin Drugs and Delivery Devices Market size is estimated at USD 65.02 billion in 2023, and is expected to reach USD 78.08 billion by 2028, growing at a CAGR of 3.73% during the forecast period (2023-2028).

Diabetes mellitus is considered a risk factor for increasing COVID-19. During the COVID-19 pandemic, tight control of glucose levels and prevention of diabetes complications might be crucial in patients with diabetes mellitus to keep susceptibility low and to prevent severe courses of COVID-19. COVID-19 affects glucose metabolism, mainly in patients with diabetes due to this frequent usage of insulin drugs and delivery devices market increased.

Diabetes is generally considered a lifestyle-related disease. Over time, with the increase in population around the world, the incidences of the disease have increased outrageously. Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes. Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. Insulin Drugs and delivery devices are necessary for type-1 diabetes patients because their body doesn't produce insulin internally, type-2 diabetes patients also need insulin, particularly those who have difficulty controlling their diabetes with oral medications.

Human Insulin Drugs and Delivery Devices Market Trends

Type-1 Diabetes Population Driving the Market In The Forecast Period

The type-1 diabetes population is expected to register a CAGR of over 2% during the forecast period.

The exact cause of type-1 diabetes is unknown, but type-2 diabetes is caused by day-to-day lifestyle changes and choices. The prevalence rate of type-2 diabetes has quadrupled when compared to a decade ago. The prevalence of type-1 diabetes mellitus (T2DM) has increased dramatically during the last two decades, a fact driven by the increased incidence of obesity, the primary risk factor for T1DM. Diabetes ranks among the fastest-growing chronic diseases in the United States. India is among the top three countries with a high incidence of diabetes. Many reports and surveys have documented a drastic increase in the diabetic population based on lifestyle habits.

Although oral anti-diabetic drugs are considered a standard of care for type-2 diabetes patients, there has been a rise in the need for using insulin, along with conventional medication, to help stabilize blood glucose levels. This trend has attracted many players, both local and international, to enter the biosimilar market.

The R&D in the insulin segment is rising year-on-year as researchers are trying to bring out the best molecule for patients' use, curb maximum side effects, and increase their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment the demand for insulin, which in turn drives the market for insulin drugs and devices.

Human Insulin Drugs and Devices Market - Type-1 Diabetes Population (in million), 2016-2021

North America is Expected to Dominate the Human Insulin Drugs and Delivery Devices Market.

North America dominates the human insulin drug and delivery device market, despite having high insulin prices. According to RAND researchers, insulin drug companies charge more for insulin in the United States than in any other country. Insulin drug companies say that the price is based on government regulations and insurance providers. For the insured, out-of-pocket costs are usually calculated as a percentage of co-insurance of the list price of insulin products. Increases in patient co-insurance, therefore, reflect rising list prices of insulin products. According to a Commonwealth Fund study, uninsured Americans with diabetes are more likely to be using older, less costly (and less effective) insulin drugs compared to those with private insurance or Medicaid. 60% to 80% of uninsured patients pay the full list price for insulin, while 9% of privately insured patients and 3% of Medicaid beneficiaries do.

Despite all these factors, the market for insulin drugs and delivery devices is high in North America because there is no other major option other than insulin. There have been several initiatives carried out in the commercial sector to address insulin affordability. The recent advent of biosimilar insulin products may help reduce out-of-pocket costs, as could the possibility of automatic interchangeability between biosimilar insulin and originator products.

Thus, owing to the above factors, it is expected to drive market growth over the forecast period.

Human Insulin Drugs and Devices Market - Growth Rate by Region, 2023-2028

Human Insulin Drugs and Delivery Devices Industry Overview

The market is highly consolidated, with three major manufacturers holding a global market presence and the remaining manufacturers confined to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Human Insulin Drugs and Delivery Devices Market Leaders

  1. Novo Nordisk

  2. Sanofi

  3. El lilly

  4. Medtronics

  5. Roche

*Disclaimer: Major Players sorted in no particular order

Human Insulin Drugs And Delivery Devices Market Concentration

Human Insulin Drugs and Delivery Devices Market News

  • October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy, and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300).
  • August 2022: Ypsomed launched bolus delivery from the smartphone on the mylife YpsoPump via the mylife App. This new feature enables mylife YpsoPump users to deliver the bolus insulin conveniently and discreetly via their smartphone, without having to interact with the pump itself.

Human Insulin Drugs & Delivery Devices Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Basal or Long Acting Insulins

        1. 5.1.1.1 Lantus (Insulin glargine)

        2. 5.1.1.2 Levemir (Insulin detemir)

        3. 5.1.1.3 Tresiba (Insulin degludec)

        4. 5.1.1.4 Toujeo (Insulin glargine)

        5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast Acting Insulins

        1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 5.1.2.2 Humalog (Insulin lispro)

        3. 5.1.2.3 Apidra (Insulin glulisine)

        4. 5.1.2.4 FIASP (Insulin aspart)

        5. 5.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 5.1.3 Traditional Human Insulins

        1. 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins

        1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 5.1.5 Biosimilar Insulins

        1. 5.1.5.1 Insulin glargine biosimilars

        2. 5.1.5.2 Human insulin biosimilars

    2. 5.2 By Device

      1. 5.2.1 Insulin Pumps

        1. 5.2.1.1 Insulin Pump Devices

        2. 5.2.1.2 Insulin Pump Reservoirs

        3. 5.2.1.3 Insulin Infusion sets

      2. 5.2.2 Insulin Pens

        1. 5.2.2.1 Cartridges in reusable pens

        2. 5.2.2.2 Disposable insulin pens

      3. 5.2.3 Insulin Syringes

      4. 5.2.4 Insulin Jet Injectors

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Rest of North America

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Russia

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Italy

        7. 5.3.2.7 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 Australia

        2. 5.3.3.2 India

        3. 5.3.3.3 China

        4. 5.3.3.4 Japan

        5. 5.3.3.5 Malaysia

        6. 5.3.3.6 South Korea

        7. 5.3.3.7 Thailand

        8. 5.3.3.8 Philippines

        9. 5.3.3.9 Vietnam

        10. 5.3.3.10 Indonesia

        11. 5.3.3.11 Rest of the Asia-Pacific

      4. 5.3.4 Latin America

        1. 5.3.4.1 Brazil

        2. 5.3.4.2 Mexico

        3. 5.3.4.3 Rest of Latin America

      5. 5.3.5 Middle-East and Africa

        1. 5.3.5.1 Saudi Arabia

        2. 5.3.5.2 Iran

        3. 5.3.5.3 Egypt

        4. 5.3.5.4 Oman

        5. 5.3.5.5 South Africa

        6. 5.3.5.6 Rest of the Middle-East and Africa

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 diabetes population

    2. 6.2 Type-2 diabetes population

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Biocon

      5. 7.1.5 Julphar

      6. 7.1.6 Exir

      7. 7.1.7 Medtronic

      8. 7.1.8 Insulet

      9. 7.1.9 Ypsomed

      10. 7.1.10 Becton Dickinson

    2. *List Not Exhaustive

    3. 7.2 Company Share Analysis

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

Human Insulin Drugs and Delivery Devices Industry Segmentation

The hormone class of drugs includes human insulin. In place of the insulin that the body ordinarily produces, human insulin is used. It assists in the movement of blood sugar into different bodily tissues, where it is used as an energy source. It also prevents the liver from generating additional sugar. The human insulin drug and delivery device market is set to witness a CAGR of more than 3% during the forecast period. The human insulin drug and delivery device market is segmented by type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins), device type (insulin pens, insulin pumps, insulin syringes, and jet injectors), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America). The report offers the value (in USD million) and volume (in units million) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

By Drug
Basal or Long Acting Insulins
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Tresiba (Insulin degludec)
Toujeo (Insulin glargine)
Basaglar (Insulin glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin glargine biosimilars
Human insulin biosimilars
By Device
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Geography
North America
United States
Canada
Rest of North America
Europe
Germany
United Kingdom
France
Russia
Spain
Italy
Rest of Europe
Asia-Pacific
Australia
India
China
Japan
Malaysia
South Korea
Thailand
Philippines
Vietnam
Indonesia
Rest of the Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle-East and Africa
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of the Middle-East and Africa

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Human Insulin Drugs & Delivery Devices Market Research FAQs

The Human Insulin Drugs and Delivery Devices Market size is expected to reach USD 65.02 billion in 2023 and grow at a CAGR of 3.73% to reach USD 78.08 billion by 2028.

In 2023, the Human Insulin Drugs and Delivery Devices Market size is expected to reach USD 65.02 billion.

Novo Nordisk, Sanofi, El lilly, Medtronics and Roche are the major companies operating in the Human Insulin Drugs and Delivery Devices Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).

In 2023, the North America accounts for the largest market share in the Human Insulin Drugs and Delivery Devices Market.

Human Insulin Drugs and Delivery Devices Industry Report

Statistics for the 2023 Human Insulin Drugs and Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Human Insulin Drugs and Delivery Devices analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Human Insulin Drugs and Delivery Devices Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!